214360-57-3

Usage

Uses

Used in Pharmaceutical Industry:
4-N-Methylcarboxamidophenylboronic acid, pinacol ester is used as a reagent in the synthesis of various pharmaceuticals for its ability to facilitate cross-coupling reactions and the formation of biaryl compounds, which are important structural motifs in many bioactive molecules.
Used in Agrochemical Industry:
4-N-Methylcarboxamidophenylboronic acid, pinacol ester is used as a reagent in the synthesis of agrochemicals to create new compounds with potential pesticidal or herbicidal properties, leveraging its reactivity in cross-coupling reactions to form complex molecular structures.
Used in Organic Chemistry Research and Development:
4-N-Methylcarboxamidophenylboronic acid, pinacol ester is used as a versatile reagent in organic chemistry research and development for its compatibility with a wide range of functional groups, enabling the creation of diverse chemical entities for various applications.

InChI:InChI=1/C14H20BNO3/c1-13(2)14(3,4)19-15(18-13)11-8-6-10(7-9-11)12(17)16-5/h6-9H,1-5H3,(H,16,17)

Upstream product

• 74-89-5 methylamine 
• 380499-68-3 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid chloride 
• 73183-34-3 bis(pinacol)diborane 
• 88070-48-8 N-methylbenzamide 
• 98-88-4 benzoyl chloride 
• 65-85-0 benzoic acid 
• 180516-87-4 4-carboxyphenylboronic acid pinacol ester 
• 14047-29-1 4-carboxyphenylboronic acid 
• 76-09-5 2,3-dimethyl-2,3-butane diol 
• 6274-22-2 4-amino-N-methyl-benzamide 
• 586-76-5 4-Bromobenzoic acid 
• 124-40-3 dimethyl amine 
• 27466-83-7 4-bromo-N-methylbenzamide 

Downstream Products

• 1332448-74-4 2'-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-N-methylbiphenyl-4-carboxamide 
• 1332450-17-5 C₂₅H₂₅N₃OS 
• 1618663-59-4 4-(2-chloro-4-cyclobutoxy-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-N-methylbenzamide 
• 1618663-92-5 4-(2-chloro-4-(3-cyanocyclobutoxy)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-N-methylbenzamide 
• 1246347-33-0 4-(4-cyclohexylamino-1H-pyrazolo[4,3-c]pyridin-3-yl)-N-methyl-benzamide 
• 1222999-45-2 C₃₆H₂₃F₃N₄O₂ 
• 862081-53-6 4-{6-methoxy-1-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-naphthalen-2-yl}-N-methyl-benzamide 

Relevant academic research and scientific papers

Hydrogen Bond Directed ortho-Selective C?H Borylation of Secondary Aromatic Amides

Reported is an iridium catalyst for ortho-selective C?H borylation of challenging secondary aromatic amide substrates, and the regioselectivity is controlled by hydrogen-bond interactions. The BAIPy-Ir catalyst forms three hydrogen bonds with the substrate during the crucial activation step, and allows ortho-C?H borylation with high selectivity. The catalyst displays unprecedented ortho selectivities for a wide variety of substrates that differ in electronic and steric properties, and the catalyst tolerates various functional groups. The regioselective C?H borylation catalyst is readily accessible and converts substrates on gram scale with high selectivity and conversion.

Amide Effects in C?H Activation: Noncovalent Interactions with L-Shaped Ligand for meta Borylation of Aromatic Amides

A new concept for the meta-selective borylation of aromatic amides is described. It has been demonstrated that while esters gave para borylations, amides lead to meta borylations. For achieving high meta selectivity, an L-shaped bifunctional ligand has been employed and engages in an O???K noncovalent interaction with the oxygen atom of the moderately distorted amide carbonyl group. This interaction provides exceptional control for meta C?H activation/borylation.

Nickel-Catalyzed Borylation of Aryl- and Benzyltrimethylammonium Salts via C-N Bond Cleavage

By developing a mild Ni-catalyzed system, a method for direct borylation of sp2 and sp3 C-N bonds has been established. The key to this hightly efficient C-N bond borylative cleavage depends on the appropriate choice of the nickel catalyst Ni(COD)2, ICy·HCl as a ligand, and the use of 2-ethoxyethanol as the cosolvent. This transformation shows good functional group compatibility and can serve as a powerful synthetic tool for gram-scale synthesis and late-stage C-N borylation of complex compounds.

GLUCOSYLCERAMIDE SYNTHASE INHIBITORS

The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, cystic disease and for the treatment of cancer.

Discovery and optimization of potent and selective benzonaphthyridinone analogs as small molecule mTOR inhibitors with improved mouse microsome stability

Starting from small molecule mTOR inhibitor Torin1, replacement of the piperazine ring with a phenyl ring resulted in a new series of mTOR inhibitors (as exemplified by 10) that showed superior potency and selectivity for mTOR, along with significantly improved mouse liver microsome stability and a longer in vivo half-life.

PYRROLO[2,3-d]PYRIMIDINES THAT MODULATE ACK1 AND LCK ACTIVITY

Compounds that modulate the action of ACK1 and LCK, and related compositions methods for treating ACK1- and LCK-mediated diseases are described. In one aspect, the compounds have the general structure: where the values of the substituents are provided her

SPIROPIPERIDINE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHERMER’S DISEASE

The present invention is directed to spiropiperidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. T

Potentiators of glutamate receptors

The present invention relates to potentiators of metabotropic glutamate receptor function and specifically provides compounds of formula I, compositions thereof and methods of using the same.

Cyclopentyl sulfonamide derivatives

The present invention provides certain cyclopentyl sulfonamide derivatives of formula (I): useful for potentiating glutamate receptor function in a mammal. It also relates to novel cyclopentyl sulfonamide derivatives, to processes for their preparation and to pharmaceutical compositions containing them.